[Polatuzumab vedotin in the treatment of relapsed or refractory DLBCL: a case report].

Diffuse large B-cell lymphomas (DLBCLs) represent one of the most common and aggressive forms of non-Hodgkin lymphoma (NHL), characterized by rapid B-cell growth and a significantly high risk of relapse or refractoriness. The clinical course for these patients is long and complicated with a sometimes dismal prognosis, and the therapeutic approach must include effective and innovative chemotherapeutic treatments. The therapeutic strategies for DLBCLs in recent years has seen considerable pharmacological enrichment, including drug-conjugated antibodies such as polatuzumab vedotin. Indeed, this drug has demonstrated its efficacy even in the age-unfit elderly patient, providing a good safety and tolerability profile. Specifically, is described the case of an elderly patient with relapsed/refractory DLBCL with extra-nodal and bone disease presentation, treated second-line with polatuzumab vedotin in combination with rituximab and bendamustine. This combination resulted in a complete clinical and metabolic response while preserving excellent drug tolerance during treatment and improving the patient's quality of life.